Skip to Content

Frequently Searched

Supported by

What Is The Buzz About A New Pancreatic Cancer Therapy?

Published Date:

Targeting a cancer-driving pathway once considered “undruggable” is bringing new possibilities to pancreatic cancer care. In our featured article, Hardeep Phull, MD, MS, examines daraxonrasib, an oral RAS inhibitor, and the clinical trial findings behind its use in previously treated metastatic pancreatic cancer.

Dr. Phull explores the science behind this targeted approach, key survival and quality-of-life findings, and what they could mean for patient care, along with questions for future research.

DOWNLOAD ARTICLE

Explore the Fall 2026 edition of Oncolytics Today

VIEW

Hardeep Phull, MD, MS, is a physician-scientist, educator, author and speaker involved with cancer care, personalized medicine and innovation in healthcare, including clinical AI. He is president of Hematology Oncology Partners in Excellence, a firm dedicated to empowering doctors with medical education and opportunities. He also serves in a leadership alumni role at the Cleveland Clinic Foundation and serves as a Clinical Instructor at the University of California San Diego.

 

  1. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. US Food and Drug Administration. August 26, 2026. Accessed August 27, 2026. https://www.fda.gov/drugs/resources-in-formation-approved-drugs/fda-approves-darax-onrasib-metastatic-pancreatic-adenocarcinoma.
  2. O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026;395(4):325-337.
  3. Wolpin BM, Wainberg ZA, Hendifar A, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastat-ic pancreatic adenocarcinoma (mPDAC): primary and final analysis from the phase 3 RASolute 302 study. J Clin Oncol. 2026;44(suppl 17):LBA5.
  4. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6(4):321-337.
  5. Sang B, Ye LF, Fu Z, Pourfarjam Y, Cuevas-Na-varro A, Fan S, et al. Disrupted molecular glue complex drives RAS inhibitor resistance. Cell. 2026;189(10):2918-2933.e17.
  6. Jiang L, Maldonato BJ, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14(6):994-1017.